Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases... Show more
ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where ENTA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ENTA's RSI Oscillator exited the oversold zone, of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for ENTA just turned positive on April 15, 2025. Looking at past instances where ENTA's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ENTA advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTA as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ENTA entered a downward trend on April 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ENTA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.963) is normal, around the industry mean (14.238). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (1.607) is also within normal values, averaging (252.967).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a developer of drugs and other pharmaceuticals products
Industry Biotechnology
A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with ALEC. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then ALEC could also see price increases.
Ticker / NAME | Correlation To ENTA | 1D Price Change % | ||
---|---|---|---|---|
ENTA | 100% | +5.14% | ||
ALEC - ENTA | 40% Loosely correlated | +1.96% | ||
BEAM - ENTA | 37% Loosely correlated | +6.32% | ||
ADCT - ENTA | 37% Loosely correlated | +0.79% | ||
VRDN - ENTA | 36% Loosely correlated | +3.99% | ||
EDIT - ENTA | 36% Loosely correlated | +4.51% | ||
More |